9
Participants
Start Date
October 31, 2015
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
Crizotinib
To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
Pembrolizumab
To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
Emory University Hospital Midtown, Atlanta
Emory University Hospital, Atlanta
The Emory Clinic, Atlanta
Winship Cancer Institute of Emory University, Atlanta
University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, IDS Pharmacy, Birmingham
University of Alabama at Birmingham, Birmingham
The Cleveland Clinic Foundation, Cleveland
City of Hope National Medical Center, Duarte
UC San Diego Medical Center - La Jolla(Thornton Hospital), La Jolla
University Of California / San Diego Moores Cancer Center, La Jolla
UC San Diego Medical Center - Hillcrest, San Diego
Swedish Cancer Institute, Seattle
Swedish Investigational Drug Services Pharmacy, Seattle
UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Pfizer
INDUSTRY